Current Headlines

  1. Zymeworks Receives U.S. FDA Fast Track Designation For ZW191, An Frα-Targeting Antibody-Drug Conjugate 3/30/2026

    Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).

  2. Insilico Medicine Announces Global R&D Collaboration With Lilly 3/29/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company (“Lilly”) that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.

  3. Jyong Biotech Updates The Potential Clinical Benefits And Advantages Of Its Plant-Derived Innovative Drug MCS®-2 3/27/2026

    Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

  4. IBM Quantum Computer Accurately Simulates Real Magnetic Materials, Reproducing National Laboratory Data 3/26/2026

    IBM (NYSE: IBM) today announced new results that its quantum computer can simulate real magnetic materials with results that match neutron scattering experiments, marking a significant step towards using quantum computers as reliable tools for scientific discovery.

  5. SEQSTER Unveils AI-Powered Patient Screening For Clinical Trials 3/26/2026

    SEQSTER PDM, Inc. (“SEQSTER”), the leading healthcare technology company powering the connection, collection, and orchestration layer of patient health data, today launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in minutes.

  6. Simulations Plus Announces Strategic Collaboration Programs For AI-Enabled Modeling 3/26/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle.

  7. Hoth Therapeutics Deploys OpenClaw™ AI Platform To Accelerate Drug Discovery 3/26/2026

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline.

  8. Purple Biotech Announces AI Collaboration With Converge Bio To Accelerate Development Of Its Next-Generation Tri-Specific Antibody Platform 3/25/2026

    Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform leveraging advanced generative AI capabilities.

  9. Xtressé™ Announces FDA IND Acceptance For Xvie, The First & Only Extracellular Vesicle Injectable Therapy For Androgenetic Alopecia 3/24/2026

    Xtressé™, the advanced hair health company founded by dermatologists and scientists, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Xvie, a regenerative therapy for androgenetic alopecia.

  10. Insilico Medicine And ASKA Pharmaceutical Expand Partnership To Discover Novel Targets For Women's Health 3/24/2026

    Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology.